{"url_path":"/sec/prld/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-343469-index.html","accession_number":"0001193125-26-343469","cik":"0001678660","ticker":"PRLD","issuer_name":"Prelude Therapeutics Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-343469-index.html","primary_entity_key":"0001678660","primary_entity_name":"Prelude Therapeutics Inc"},"word_count":132,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\n \n\nOn August 11, 2026, Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe information in this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished, but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing."}